SIMG
SUPN icon

Stephens Investment Management Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Stephens Investment Management Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$69.9M Sell
1,351,331
-55,191
-4% -$2.81M 0.96% 31
2025
Q4 		$69.9M Buy
1,406,522
+61,120
+5% +$2.97M 0.91% 39
2025
Q3 		$64.3M Sell
1,345,402
-235,691
-15% -$9.49M 0.83% 44
2025
Q2 		$49.8M Sell
1,581,093
-157,389
-9% -$5.04M 0.66% 59
2025
Q1 		$56.9M Sell
1,738,482
-13,586
-0.8% -$481K 0.82% 45
2024
Q4 		$63.4M Sell
1,752,068
-180,141
-9% -$6.34M 0.85% 43
2024
Q3 		$60.2M Buy
1,932,209
+33,710
+2% +$1.05M 0.82% 48
2024
Q2 		$50.8M Sell
1,898,499
-3,277
-0.2% -$95K 0.71% 58
2024
Q1 		$64.9M Sell
1,901,776
-3,088
-0.2% -$91.9K 0.86% 45
2023
Q4 		$55.1M Buy
1,904,864
+200,166
+12% +$5.31M 0.81% 56
2023
Q3 		$47M Buy
1,704,698
+3,983
+0.2% +$121K 0.77% 58
2023
Q2 		$51.1M Buy
1,700,715
+38,453
+2% +$1.35M 0.8% 58
2023
Q1 		$60.2M Buy
1,662,262
+57,493
+4% +$2.21M 1.01% 35
2022
Q4 		$57.6M Sell
1,604,769
-1,037
-0.1% -$36K 1.04% 29
2022
Q3 		$54.4M Sell
1,605,806
-6,576
-0.4% -$214K 1.03% 24
2022
Q2 		$46.6M Buy
1,612,382
+11,038
+0.7% +$316K 0.86% 47
2022
Q1 		$51.8M Buy
1,601,344
+23,364
+1% +$716K 0.76% 59
2021
Q4 		$46M Buy
1,577,980
+337,902
+27% +$10.3M 0.59% 83
2021
Q3 		$33.1M Sell
1,240,078
-5,251
-0.4% -$141K 0.45% 98
2021
Q2 		$38.3M Buy
1,245,329
+104,810
+9% +$3.21M 0.53% 92
2021
Q1 		$29.9M Buy
1,140,519
+295,141
+35% +$8.25M 0.43% 103
2020
Q4 		$21.3M Buy
845,378
+546,738
+183% +$11.8M 0.32% 112
2020
Q3 		$6.22M Buy
298,640
+29,218
+11% +$663K 0.11% 148
2020
Q2 		$6.4M Sell
269,422
-11,525
-4% -$255K 0.12% 140
2020
Q1 		$5.05M Buy
280,947
+894
+0.3% +$18.8K 0.12% 136
2019
Q4 		$6.64M Sell
280,053
-6,179
-2% -$150K 0.12% 138
2019
Q3 		$7.87M Sell
286,232
-20,390
-7% -$604K 0.16% 132
2019
Q2 		$10.1M Buy
306,622
+96,494
+46% +$3.31M 0.19% 130
2019
Q1 		$7.36M Sell
210,128
-663
-0.3% -$24.7K 0.15% 138
2018
Q4 		$7M Buy
210,791
+36,150
+21% +$1.55M 0.17% 138
2018
Q3 		$8.79M Sell
174,641
-12,589
-7% -$622K 0.16% 138
2018
Q2 		$10.9M Buy
187,230
+4,630
+3% +$240K 0.22% 130
2018
Q1 		$8.36M Sell
182,600
-993
-0.5% -$41.4K 0.18% 135
2017
Q4 		$7.32M Buy
+183,593
New +$7.25M 0.17% 142

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stephens Investment Management Group's SUPN Position: Q1 2026 in Review

Stephens Investment Management Group reduced its Supernus Pharmaceuticals (SUPN) stake by 3.9% in Q1 2026, selling an estimated $2.81M and leaving 1,351,331 shares worth $69.9M. The position accounts for 0.96% of the portfolio, ranked #31.

Stephens Investment Management Group first reported a position in SUPN in Q4 2017 and has held it in 34 quarters since. The position peaked at $69.9M in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Stephens Investment Management Group held 1,351,331 shares of Supernus Pharmaceuticals worth $69.9M as of Q1 2026.
  • Stephens Investment Management Group sold 55,191 Supernus Pharmaceuticals shares in Q1 2026, an estimated $2.81M.
  • Supernus Pharmaceuticals made up 0.96% of Stephens Investment Management Group's portfolio in Q1 2026, its #31 holding.
  • Stephens Investment Management Group first reported a position in Supernus Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
  • Stephens Investment Management Group's Supernus Pharmaceuticals position peaked at $69.9M in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Stephens Investment Management Group's 13F filing for Q1 2026, filed 28 Apr 2026.